Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to ...

Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results ...

Camp4 Therapeutics Corporation’s CAMP share price has dipped by 18.47%, which has investors questioning if this is right time to buy.

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

Discover the top genomics startups revolutionizing genome sequencing technologies to enhance disease prevention and treatment ...

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

"Everything injected into the bloodstream is eventually ends up in the liver — that's just how our anatomy works," Professor ...

Atalanta aims to create disease-modifying therapies by silencing certain genes in the central nervous system, including in the brain and spinal cord.